Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey.


Journal

Lipids in health and disease
ISSN: 1476-511X
Titre abrégé: Lipids Health Dis
Pays: England
ID NLM: 101147696

Informations de publication

Date de publication:
04 May 2021
Historique:
received: 04 03 2021
accepted: 15 04 2021
entrez: 5 5 2021
pubmed: 6 5 2021
medline: 25 11 2021
Statut: epublish

Résumé

Although patients with familial heterozygous hypercholesterolemia (FH) have a high risk of early myocardial infarction (MI), the coronary artery disease (CAD) burden in FH patients with acute MI remains to be investigated. The data for all consecutive patients hospitalized in 2012-2019 for an acute MI and who underwent coronary angiography were collected from a multicenter database (RICO database). FH (n = 120) was diagnosed using Dutch Lipid Clinic Network criteria (score ≥ 6). We compared the angiographic features of MI patients with and without FH (score 0-2) (n = 234) after matching for age, sex, and diabetes (1:2). Although LDL-cholesterol was high (208 [174-239] mg/dl), less than half of FH patients had chronic statin treatment. When compared with non-FH patients, FH increased the extent of CAD (as assessed by SYNTAX score; P = 0.005), and was associated with more frequent multivessel disease (P = 0.004), multiple complex lesions (P = 0.022) and significant stenosis location on left circumflex and right coronary arteries. Moreover, FH patients had more multiple lesions, with an increased rate of bifurcation lesions or calcifications (P = 0.021 and P = 0.036, respectively). In multivariate analysis, LDL-cholesterol levels (OR 1.948; 95% CI 1.090-3.480, P = 0.024) remained an independent estimator of anatomical complexity of coronary lesions, in addition to age (OR 1.035; 95% CI 1.014-1.057, P = 0.001). FH patients with acute MI had more severe CAD, characterized by complex anatomical features that are mainly dependent on the LDL-cholesterol burden. Our findings reinforce the need for more aggressive preventive strategies in these high-risk patients, and for intensive lipid-lowering therapy as secondary prevention.

Sections du résumé

BACKGROUND BACKGROUND
Although patients with familial heterozygous hypercholesterolemia (FH) have a high risk of early myocardial infarction (MI), the coronary artery disease (CAD) burden in FH patients with acute MI remains to be investigated.
METHODS METHODS
The data for all consecutive patients hospitalized in 2012-2019 for an acute MI and who underwent coronary angiography were collected from a multicenter database (RICO database). FH (n = 120) was diagnosed using Dutch Lipid Clinic Network criteria (score ≥ 6). We compared the angiographic features of MI patients with and without FH (score 0-2) (n = 234) after matching for age, sex, and diabetes (1:2).
RESULTS RESULTS
Although LDL-cholesterol was high (208 [174-239] mg/dl), less than half of FH patients had chronic statin treatment. When compared with non-FH patients, FH increased the extent of CAD (as assessed by SYNTAX score; P = 0.005), and was associated with more frequent multivessel disease (P = 0.004), multiple complex lesions (P = 0.022) and significant stenosis location on left circumflex and right coronary arteries. Moreover, FH patients had more multiple lesions, with an increased rate of bifurcation lesions or calcifications (P = 0.021 and P = 0.036, respectively). In multivariate analysis, LDL-cholesterol levels (OR 1.948; 95% CI 1.090-3.480, P = 0.024) remained an independent estimator of anatomical complexity of coronary lesions, in addition to age (OR 1.035; 95% CI 1.014-1.057, P = 0.001).
CONCLUSIONS CONCLUSIONS
FH patients with acute MI had more severe CAD, characterized by complex anatomical features that are mainly dependent on the LDL-cholesterol burden. Our findings reinforce the need for more aggressive preventive strategies in these high-risk patients, and for intensive lipid-lowering therapy as secondary prevention.

Identifiants

pubmed: 33947397
doi: 10.1186/s12944-021-01467-z
pii: 10.1186/s12944-021-01467-z
pmc: PMC8094609
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

45

Subventions

Organisme : ARS Bourgogne-Franche-Comté (FR)
ID : NA
Organisme : CHU Dijon Bourgogne
ID : NA
Organisme : Association de Cardiologie de Bourgogne
ID : NA
Organisme : Conseil régional de Bourgogne-Franche-Comté
ID : NA

Références

Atherosclerosis. 2005 Apr;179(2):293-7
pubmed: 15777544
Jpn Circ J. 2001 Apr;65(4):247-50
pubmed: 11316116
J Am Coll Cardiol. 2016 Oct 25;68(17):1851-1864
pubmed: 27595509
Arch Intern Med. 2003 Oct 27;163(19):2345-53
pubmed: 14581255
Presse Med. 2019 Mar;48(3 Pt 1):227-237
pubmed: 30853281
J Cardiol. 2020 Jun;75(6):654-658
pubmed: 31992496
N Engl J Med. 2016 Oct 27;375(17):1628-1637
pubmed: 27783906
Catheter Cardiovasc Interv. 2019 Aug 1;94(2):187-194
pubmed: 30681262
Eur Heart J. 2020 Jan 1;41(1):111-188
pubmed: 31504418
Lipids Health Dis. 2019 Jun 1;18(1):131
pubmed: 31153370
J Am Coll Cardiol. 2016 Jun 7;67(22):2578-89
pubmed: 27050191
N Engl J Med. 2017 Sep 21;377(12):1197-1198
pubmed: 28844177
J Clin Lipidol. 2019 Jan - Feb;13(1):194-200
pubmed: 30472278
Eur Heart J. 2013 Dec;34(45):3478-90a
pubmed: 23956253
J Clin Lipidol. 2018 May - Jun;12(3):685-692.e2
pubmed: 29574074
Arterioscler Thromb Vasc Biol. 2017 Mar;37(3):570-579
pubmed: 27932355
J Clin Lipidol. 2019 Jan - Feb;13(1):115-122
pubmed: 30344049
J Clin Med. 2020 Dec 27;10(1):
pubmed: 33375401
J Am Coll Cardiol. 2016 Aug 23;68(8):789-801
pubmed: 27539170
J Cardiovasc Med (Hagerstown). 2018 Feb;19(2):75-77
pubmed: 29251697
JACC Cardiovasc Imaging. 2020 Apr;13(4):1090-1092
pubmed: 31843585
PLoS One. 2017 Oct 31;12(10):e0186815
pubmed: 29088271
J Am Coll Cardiol. 2017 Oct 31;70(18):2213-2223
pubmed: 29073947
Ann Cardiol Angeiol (Paris). 2002 Jan;51(1):8-14
pubmed: 12471655
Am Heart J. 2007 Aug;154(2):330-5
pubmed: 17643584
Eur Heart J. 2018 Dec 7;39(46):4112-4121
pubmed: 30203006
Am Heart J. 2016 Nov;181:35-42
pubmed: 27823691
J Clin Lipidol. 2020 May - Jun;14(3):352-360.e6
pubmed: 32527469
J Clin Endocrinol Metab. 2012 Nov;97(11):3956-64
pubmed: 22893714
Coron Artery Dis. 2020 Aug;31(5):438-445
pubmed: 32040027
Am J Cardiol. 1983 Feb;51(3):606
pubmed: 6823874
J Clin Lipidol. 2019 Jul - Aug;13(4):601-607
pubmed: 31324593
Atherosclerosis. 2020 Apr;298:52-57
pubmed: 32171980
N Engl J Med. 2005 Jan 6;352(1):29-38
pubmed: 15635110
Circulation. 2016 Sep 6;134(10):698-709
pubmed: 27462068
J Clin Med. 2021 Feb 13;10(4):
pubmed: 33668494
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
J Clin Lipidol. 2019 May - Jun;13(3):502-508
pubmed: 30956097

Auteurs

Hermann Yao (H)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.

Michel Farnier (M)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.

Laura Tribouillard (L)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.
PEC2, EA 7460, UFR Health Sciences, University of Bourgogne Franche Comté, Dijon, France.

Frédéric Chague (F)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.

Philippe Brunel (P)

Private Hospital Dijon Bourgogne, Dijon, France.

Maud Maza (M)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.

Damien Brunet (D)

Private Hospital Dijon Bourgogne, Dijon, France.

Luc Rochette (L)

PEC2, EA 7460, UFR Health Sciences, University of Bourgogne Franche Comté, Dijon, France.

Florence Bichat (F)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.

Yves Cottin (Y)

Cardiology Department, University Hospital Center Dijon Bourgogne, Dijon, France.

Marianne Zeller (M)

PEC2, EA 7460, UFR Health Sciences, University of Bourgogne Franche Comté, Dijon, France. Marianne.zeller@u-bourgogne.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH